Oncology Nursing News®

Skin Cancer/Melanoma

FDA Approves Pembrolizumab for Advanced Merkel Cell Carcinoma

FDA Approves Pembrolizumab for Advanced Merkel Cell Carcinoma

BY GINA COLUMBUS

SITC Updates Immunotherapy Guidelines for Melanoma

SITC Updates Immunotherapy Guidelines for Melanoma

BY JASON HARRIS

Shared Decision Making Key in Choosing Adjuvant Treatments for Melanoma

Shared Decision Making Key in Choosing Adjuvant Treatments for Melanoma

BY TONY HAGEN

Dabrafenib/Trametinib Continues to Show RFS Benefit in BRAF+ Melanoma

Dabrafenib/Trametinib Continues to Show RFS Benefit in BRAF+ Melanoma

BY STAFF

FDA Approves Cemiplimab for CSCC

FDA Approves Cemiplimab for CSCC

BY JASON M. BRODERICK

FDA Grants Priority Review to Pembrolizumab for Advanced Merkel Cell Carcinoma

FDA Grants Priority Review to Pembrolizumab for Advanced Merkel Cell Carcinoma

BY KRISTIE L. KAHL

FDA Approves Binimetinib/Encorafenib for BRAF+ Melanoma

FDA Approves Binimetinib/Encorafenib for BRAF+ Melanoma

BY JASON M. BRODERICK

Exploring the Need for Better Melanoma Surveillance

Exploring the Need for Better Melanoma Surveillance

BY BRIELLE URCIUOLI

FDA Approves Adjuvant Treatment Combination for Patients With BRAF+ Melanoma

FDA Approves Adjuvant Treatment Combination for Patients With BRAF+ Melanoma

BY JASON M. BRODERICK

FDA Grants Priority Review to Cemiplimab for Treatment of Metastatic CSCC

FDA Grants Priority Review to Cemiplimab for Treatment of Metastatic CSCC

BY JASON M. BRODERICK

External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc

OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives

About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.